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Loading and Maintenance Doses of Digoxin in
Patients with Normal Renal Function and
Those with Severely Impaired Renal Function
JOHN G. WAGNER. Ph.D. Ann Arbor, Mich.
T HE clinician may find the equations
and terminology in this report confus-
ing and difficult to follow. However, phar-
inacokinetic theory is of little use unless
those familiar with the theory show how
application of the theory is of practical
importance. This paper is an attempt to
do so with a drug that has presented many
problems with respect to dosing and
toxicity. It is really not important that
the clinician completely understand how
the results were calculated; it is important
for him or her to remember the results for
each drug for which the equations were
applied.
The arguments are presented in the
text, and the equations in the Appendix,
so that those familiar with pharmaco-
kinetic theory can apply them to other
drugs and produce still more practical in-
formation for the busy clinician. The prin-
cipal role of the clinician, with respect to
the aspect of medicine discussed in this
report, is to determine the relationship
between clinical effect and dose of a drug.
The principal roles of the pharmaco-
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kineticist, with respect to the same aspect,
are: (1) to develop models from observed
measurements such as plasma concentra-
tions; (2) to show the relationship be-
tween the clinical effect and some observed
or model-calculated values; and (3) to
make recommendations concerning the ap-
propriate way to obtain maximum benefit
from a given dose of the drug and, at the
same time, reduce the chance of toxicity
to as low a probability as possible.
Jelliffe1 has suggested that it is not
necessary to change the loading dose of
digoxin in patients with renal failure.
Chung2 recommends that the loading dose
of digoxin be decreased to from one third
to two thirds of the usual loading dose.
Reuning et al.3 suggested “that the load-
ing dose of digoxin for such patients
should be decreased to one half to two
thirds of the normal loading dose in order
to achieve blood levels in the desired
therapeutic range.” This author agrees
with the figure of two thirds if blood
levels are the appropriate criterion. How-
ever, this author believes that the report
of Reuning et al.3 indicates that the aver-
uge amount of drug in the second com-
partment of the two-compartment open
model is the appropriate criterion; using
this criterion, the loading dose should be
the same in severely impaired renal pa-
tients as it is in normal patients.
Reuning et al.8 also stated, “The optimal
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loading dose for digoxin does not depend
on how rapidly the drug is excreted but
rather upon how large a body space must
be ‘filled up’ to a therapeutic level by the
initial dose.” This statement is erroneous,
since for any model, any drug, or any
criterion the loading dose must always be
related to the rate of elimination of the
drug as well as the volume which needs
to be filled. In the two-compartment open
model, the volume that needs to be “ifiled
up” is what is called the volume of distri-
bution steady state, d As seen below,
Vd,, for severely impaired renal patients
averages 364 liters and for patients with
normal renal function, it averages 520
liters. Hence, on the basis of volume
effects only, one would calculate that the
loading and maintenance doses in severely
impaired renal patients should both be
decreased to 70 per cent (364/520X100)
of the doses for patients with normal
renal function.
But this is an incorrect estimate, since
the rate of elimination of digoxin in the
two types of patients must also be taken
into consideration in estimating loading
and maintenance doses. If you have a
leaky bucket and you try to fill the bucket
up to a certain level with water, it is
obvious that the amount of water needed
is dependent upon the size of the holes in
the bucket! In pharmacokinetics, the most
important factor determining the size of
the loading dose is the fraction of each
dose that is eliminated from the body in
each dose interval. This fraction is equal
to /‘r, or its equivalent, 1.443 t/r, where
t is the half-life of elimination and r is
the uniform dosing interval.
The recommended loading doses of
digoxin for patients with, normal renal
function in the literature are too high for
the following reasons. First, the recom-
mendations are based upon the one corn-
partmen t open model, whereas Reunlng
et al.3 and others have shown that plasma
concentration data following intravenous
administration of digoxin are explained
by the two-compartment open model. The
loading dose based on the two-compart-
ment open model will always be less than
the loading dose based on the one-com-
partment open model. Secondly, the elimi-
nation half-life of digoxin used in the cal-
culation of the loading has frequently
been too high. Third, the loading dose
needed is directly proportional to the
maintenance dose of digoxin required
to produce the desired clinical effect.
It has been reported4 that 75 per
cent of patients are maintained on
0.25 mg/day or 0.375 mg average (0.5
mug one day and 0.25 mg the next day), 20
per cent of patients are maintained on 0.5
mg/day, and 5 per cent on 0.75 mg/day.
Hence for a new patient with normal
renal function, it appears that one should
calculate the loading dose on the basis of
a maintenance dose of 0.25 mg/day, fol-
low this loading dose with maintenance
doses of 0.25 mg/day, and then adjust the
maintenance dose on an individual pa-
tient basis to obtain the desired clinical
effect in that patient.
The two-compartment open model is
schematically shown in scheme I below.
compartment 2 A2 i
k21
coiiipartiiient 1 -4i - -
scheme I
where k12, k21, and ket are first-order rate
constants, A represents the amount of
drug at time t, and the subscripts 1 and 2
refer to the compartment number. The
amount of drug, A1, divided by the ap-
parent volume of compartment 1, V1, is
the “plasma concentration” of the drug at
time t.
Reuning et al.3 showed that the left
ventricular ejection time index and the
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Q-S2 interval correlated with the fraction
of the digoxin dose in compartment 2
(and not with the fraction of the dose of
digoxin in compartment 1). Thus, the re-
sponse to digoxin is correlated with “tissue
levels” and not with plasma levels, as
might be expected, since cardiac tissue
would be expected to be included in com-
partment 2 and not in compartment 1.
The maintenance doses of digoxin in
patients with severe renal failure must be
reduced since their kei, hereafter called
(kej) r, is smaller (about one half) than the
kei, hereafter called (kei)n, of patients
with normal renal function. Since the re-
sponse to digoxin is proportional to the
average amount of drug in compartment
2, A2, at steady state, then one should cal-
culate the loading dose on the basis that
severely impaired renal patients will have
the same value of A2 at steady state as
patients with normal renal function. That
is, one should calculate to make (A2) r
(A2) ,,, where the subscript r refers to
severely impaired renal patients and the
subscript n refers to patients with normal
renal function. This type of calculation
gives a totally different result than a cal-
culation based on making the steady-state
plasma concentrations equal [i.e., (C) ,.
(a),,]. Hence, the problem with the recom-
mendation of Reuning et al.3 was use of
the plasma level criterion rather than the
A2 criterion. This is unfortunate, since it
was they who showed that A2 was the im-
portant factor in the response.
Methods
We can set up three criteria and de-
termine what the result would be by each
criterion. These criteria are as follows:
Criterion 1. The maintenance dose ratio
R1, equal to Dr/Dn, will be such as to pro-
vide equal steady-state plasma concentra-
tions in both severely impaired renal pa-
tients and in patients with normal renal
function [i.e., (C)r= (C),].
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Criterion 2. The maintenance dose ratio
112 will be such as to provide equal steady-
state average amounts of drug in the
body, Ab (where A=A1+A2) [i.e.,
(Ab) r (ATb)n#{149}
Criterion 3. The maintenance dose ratio
R3 will be such as to provide equal steady-
state average amounts of. drug in com-
partment 2, A2 [i.e., (A2)r= (A2)].
Pharmacokinetic equations given in the
Appendix show how the ratios R1, R2, and
113 are calculated.
Reuning et al.3 reported parameter
values of digoxin for the model shown in
scheme I, both for patients with severely
impaired renal function and patients with
normal renal function. From their values,
weighted mean parameter values were
calculated. Also, from these weighted
mean parameter values, various other
needed parameters were calculated.
Results
The weighted mean parameter values
and other needed parameters, calculated
from the data presented by Reuning et
al.,3 are shown in Table I. Definitions of
the calculated parameters are given in the
footnotes to Table I.
The ratios of maintenance doses, R, 112,
and 113, needed to meet criteria 1 through 3
were calculated using the equations in the
Appendix and are tabulated in Table II.
One can see from Table II that, to pro-
duce equal steady-state plasma concentra-
tions, the maintenance dose of digoxin in
patients with severely impaired renal
failure should only be one third of the
maintenance dose of digoxin given to pa-
tients with normal renal function. How-
ever, to produce both equal steady-state
average amounts of digoxin in the body
and equal steady-state average amounts of
digoxin in compartment 2, the mainte-
nance dose of digoxin in patients with
severely impaired renal function should
be only about one half (round-off of 0.46









Par ametcr* renal function subjects
Weighted Means
IC12 (hr-i) 0.45 0.56
IC21 (hr-i) 0.113 0.15
IC,1 (hr-i) 0.040 0.081





t (hr) 91.2 44.2
Vd,, (liters) 364. 520.





#{189}[(IC12+ 1c21 + IC,1) + V (IC12 + IC21 + k,1)2 - 4k21k,iJ;
= #{190}[(ICi2 + IC21 + IC,1) - / (IC12 + IC21 + k,i)2_4k21k,.iJ;
t,=0.693/p; V4,,=V1 [1+ (k12/k21)J; V= (IC,1/p) (Vj) ; C.F.
Vd”









digoxin given to patients with normal
renal function. Because of the correla-
tions reported by Reuning et al.,3 the
author believes that the proper ratio is
given by criteria 2 and 3 and not by
criterion 1.
As indicated by eq. (9) of the Ap-
pendix, the appropriate loading dose D*
is equal to the drug accumulation ratio
multiplied by the maintenance dose.
Such a loading dose D* would with one
dose provide the same average amount
of drug in the body (Ab) as would be
ultimately attained if one gave no loading
dose but only maintenance doses of size
D at once-a-day intervals. The calculated
value of for patients with severely im-
l)aired renal function is 5.0 (round-off of
5.2), and the calculated value of RA for
patients with normal renal function is
2.5 (round off of 2.4) (see Table I).
Hence, for digoxin one has the result that
the ratio of (Ri)r/(R.t)n5/2.5=2, and
the ratio of maintenance doses is Dr/Dn
0.5/11/2; thus, the loading doses should
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TABLE II
Ratio of Maintenance Dose of Dogixin for Patients with Severely
Impaired Renal Function to Maintenance Dose of Digoxin for









1 Equal steady-state plasma con-
centrations
R1 0.33 eq. (11)
2 Equal steady-state amounts of
drug in body
R2 0.47 eq. (12)
3 Equal steady-state amounts of
drug in compartment 2
N3 0.46 eq. (13)
be the same in both severely impaired
renal patients and patients with normal
renal function. This result obviously re-
sults from the conclusion made in this re-
port that the criterion 3 is the correct
one and that criterion 2 gives essentially
the same result for digoxin as criterion 2.
If one argues that the steady-state
plasma concentrations should be equal in
the two types of patients, then the ratio
of loading doses will be:
(D*),. (N4), #{149}D, 5
_______- -- #{149}(0.33) =0.67.
(D*), (N4),, . D, 2.5
Thus, criterion 1 gives the result that
the loading dose in patients with severely
impaired renal function should be only
two thirds of the loading dose given to pa-
tients with normal renal function. How-
ever, as stated formerly, this author does
not believe that criterion 1 is the correct
one for digoxin based on the data of
Reuning et al.3
Table III gives calculated loading and
maintenance doses of digoxin in patients
with severely impaired renal function and
calculated loading doses of digoxin in pa-
tients with normal renal function, based
on the maintenance dose of digoxin re-
quired to produce the desired clinical
effect in patients with normal renal func-
tion. Since obviously the clinician does
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not know a priori what maintenance dose
of a corresponding normal patient to use,
it appears safest to use the maintenance
dose of 0.25 mg in the normal patient;
and this is why this dose and the other
corresponding doses are underlined in
Table III. This seems to be the “safest,”
since 75 per cent of patients are main-
tained on either 0.25 or 0.375 mg digoxin
per day.4 As stated formerly, the main-
tenanee dose can then be adjusted later
on an individual patient basis to produce
the desired clinical effect of the drug. To
be still “safer,” the loading dose should be
administered in several parts, as indi-
cated in the footnote to Table III. Such a
recommendation has beemi made formerly.5
Discussion
One must remember that when digoxin
is administered orally, not all of the dose
administered reaches the bloodstream of
the patient. For the Lanoxin brand of
digoxin tablets, an average of about 60
per cent of the administered dose reaches
the bloodstream.6 For many generic tab-
lets that have been studied, the percentage
is lower and variable from brand to
brand.7 Since most clinicians use. the
Lanoxin brand of digoxin tablets, the
recommendations in Table III are only
based on this brand. If the loading dose is
WAGNER
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TABLE III
Loading and Maintenance Doses of Digoxin Based on the
Pharmacokinetic Analysis Presented in this Report*
Maintenance dose Maintenance dose Recommemled
in patients with in patients with loading dose for
normal renal severely impaired both types of








* if the loading dose is administered intravenously the values in
column 3 should be reduced by multiplying them by 0.6.
f This loading dose should be divided into five equal parts and
three parts given during the first day and two parts given during
the second day; then the maintenance dose should be given on
day 3 and all subsequent days until a dosage adjustment is made.
administered intravenously, all the figures
in column 3 of Table III should be re-
duced by multiplying them by 0.6.
The recommendations of this report
agree with those of Jelliffe,1 but disagree
with those of Chun2 and Reuning et al.3
Also, the loading doses recommended in
column 3 of Table III are appreciably
lower than those recommended in prior
literature. For example, Ogilvie and
Ruedy5 recommended a loading dose of
0.0075 mg of digoxin per pound of lean
body weight and a maintenance dose of
33.3 per cent of the loading dose if the
blood urea nitrogen is >20 mg/100 ml.
For a 70-kg man (154 lb), these recom-
mendations are equivalent to a loading
dose of 1.155 mg and a maintenance dose
of 0.385 mg/day. This author believes
that such an average man should initially
receive a loading dose of 0.625 mg of
digoxin, as Lanoxin tablets orally, and
maintenance doses of 0.25 mg/day, and
that the dose be then adjusted to produce
the desired clinical effect in the particular
patient.
The recommended loading dose of
0.9625 mg, corresponding to a mainte-
nance dose of 0.385 mg/day, is lower than
the recommended loading dose of Ogilvie
and Ruedy5 of 1.155 mg since Ogilvie and
Ruedy’s loading dose is based on the one-
compartment open model (i.e., their Rd
value is 1/$r1/0.3333), while the
value in Table III is based on the two-
compartment model, so that Rd is given
by [1 + (k12/k21) I /keir4.73/1.942.5.
Smith,8 in a recent review, listed the usual
oral maintenance doses of digoxin as
0.25-0.5 mg/day and the average oral
digitalizing dose as 1.25-1.5 mg. The
ratios of loading dose/maintenance dose
calculated from these values of Smith,
namely, 3 to 5, are again higher ap-
preciably than the value of 2.5 used to
prepare Table III and which is based on
the pharmacokinetic analysis.
The effect of too high a loading dose
relative to the maintenance dose is well
illustrated by the data of Marcus et al.9
in the dog. Assuming that 30 per cent of
the digoxin is excreted daily in the dog,
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they calculated that at the end of six
days the amount of digoxin in the dog’s
body would be 0.412 mg when the dog was
dosed with 0.2 mg digoxin/day. Instead
of administering 0.412 mg digoxin (which
in this case is the appropriate loading
dose), they administered a loading dose of
0.75 mg digoxin followed by maintenance
doses of 0.2 mg/day. On the latter
regimen, they calculated that at the end
of six days the amount of digoxin in the
body would be 0.476 mg digoxin. They
measured minimum blood concentrations
each day just before dosing. The curve
for the loading dose group peaked on day
2 at about 2.2 ng/ml, then slowly de-
creased in staircase fashion to a concen-
tration somewhat above 1 ng/ml at the
end of the six days. The dogs that only
received 0.2 mg/day showed an ascending
plasma level curve which at the end of
the sixth day was still slightly less than
I ng/ml.
This author believes that such “over-
shoot” caused by too high a loading dose
may cause many of the problems as-
sociated with digoxin therapy. Most re-
ports have given only minimum plasma
or blood levels measured just before doses.
These will show the “overshoot” as indi-
cated above. However, measurement of
plasma levels during the absorption-dis-
tribution phase of digoxin would show
that too high a loading dose would cause
very high peak concentrations of digoxin
at about 1 to 2 hours after oral dosing and
even higher concentrations at time zero
when the drug is administered intra-
venously. The author believes that these
high peaks produced with too high load-
ing doses may cause much of the toxicity
observed; but, of course, this is only an
opinion and would require experimental
verification.
The equations in the Appendix are
applicable to any drug. Since the
parameter values are different for each
drug, one must substitute the appropriate
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parameter values into the equations to
calculate the ratios for a particular drug.
Hence, the values reported here for
digoxin should not he interpreted as being
aJ)plieahlc to any other drug.
Appendix
Wagner et altm#{176}gave the general eq. (1) for
the average plasma (blood or serum) concen-





where F is the fraction of each maintenance
dose D which is absorbed, r is the uniform
dosing interval, v is an apparent volume of
distribution, and K is a first-order rate con-
stant for elimination from the central com-
partment. For each type of pharmacokinetic
model, one must determine what V and K to
substitute iiito eq. (1). Gibaldi et al.u showed
that for the two-compartment open model, V
is replaced by Vd,,,,., and K is replaced by




If A,1 is the average amount of drugs in the
body at steady state (also equal to the amount
of drug that goes into and out of the body
during one dosage interval at the steady
state), then for the one-compartment open




since, for this simplest model, Kflk1 0f
the two-compartment model. Now in both the
one- and two-compartment models, /3 means
the first-order rate constant estimated from
terminal plasma concentrations such that the
half-life of elimination, t, is given by eq. (4)
(the pharmacokinetic definition of /3 is given
as a footnote to Table I):
t} =0.693/pS (4)
Perrier and Gibaldii2 showed that for the




The drug accumulation ratio BA, as given
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by Wagner,13 is the ratio of the average concentration in patients with normal renal
amount of drug in the body at steady state
to the amount of drug absorbed following ad-
ministration of one maintenance dose. This
relationship is given in eq. (6) :
function, (C) ,, we must solve
then make a ratio of two of
equations (the numerator for
paired and the denominator




RA=Ab/FD. (6) The result is
(11)
(7) when Fr=Fn and r,in. The subscript r
refers to the parameter value for patients
with severely impaired renal function, and the
subscript n refers to the parameter value for
patients with normal renal function.
Criterion 2. To make the steady-state aver-
age amount of drug in the body in severely
(8) impaired renal patients, (Ab)r, equal to the
steady-state average amount of drug in the
body of patients with normal renal function,
we must solve eq. (5) for D and make
a ratio of two of the equations as before. The
result is
Hence, for the one-compartment open model,
by using eqs. (3) and (6), one obtains
1
fir
For the two-compartment open model, by






By comparing eqs. (5), (7), and (8), one
can see that the quantity f3/k1 [1 + (k12/k21)]
is a “correction factor” which must be applied
if the drug really obeys the two-compartment
open model rather than the one-compartment
open model.
If only maintenance doses of size D are
given at uniform time intervals r, one
eventually reaches a steady state such that
the average amount of drug Ab is in the body.
The purpose of a loading dose is to quickly
establish the amount of A,1 in the body so that
one does not have to wait a long time (i.e.,
administration of many small doses) before
that level is reached. This is particularly im-
portant with long half-life drugs, since the
time to reach, say, 95 per cent of the steady-
state value A,1 is directly proportional to the
half-life of the th-ug. Hence, the appropriate











when Fr F,, and r, = r,,.
Criterion 3. To make the average amount
of drug in compartment 2 at steady state in
patients with severely impaired renal func-
tion, (A2), equal to the average amount of
drug in compartment 2 at steady state in pa-
tients with normal renal function, (A0),,, we
must solve eq. (10) for D and make a ratio
of two of the resulting equations as before.
The result is
(9) D,. (IC12), (IC21), (IC,i),.
#{149} (13)
That is, the proper loading dose D is just D, (IC12). (IC21), (ic,j),,
the accumulation ratio Ra times the mainte-
iiance dose D. when F,F,, and r,=rn.
It is also easily shown that the average It should be noted that the concept of drug
amount of drug in compartment 2 of the two- accumulation as the buildup of the amount
compartment open model at steady state is of drug in the body, as given by Wagner13
and in this report, is different than that of
k12FD Kriiger-Thiemer14’15 who considered drug ac-
(10) cumulation as the buildup of drug concentra-
tions. If one defines drug accumulation on the
basis of buildup of drug concentration, then
there will always be drug accumulation on
multiple dosing of a drug unless the doses are
spaced an infinitely long time apart. How-
ever, if one bases the definition on the amount
given by
Criteria Discussed in Text
Criterion 1. To make the steady-state plasma
concentration in severely impaired renal pa-
tients, (C),, equal to the steady-state plasma
WAGNER
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of drug in the body related to the amount
absorbed from each maintenance dose, then
there is no accumulation providing the dosing
interval is equal to, or greater than, the time
constant of elimination of the drug (i.e.,
r 5 1//3). This makes much more sense to the
author. The problem of side effects and
toxicity arises when r is made much less than
1/fl, particularly ill the use of long half-life
drugs. There is a relationship, however, be-
tween loading dose recommendations made
by Kriiger-Thiemer14 and those indicated by
eqs. (7) and (9) of this report. For the one-
compartment open model with first-order ab-
sorption rate constant IC5 and elimination rate
constant K, Kriiger-Thiemer14 gave eq. (14)
to calculate the loading dose:
D
D*=
1 - e -Kr
(14)
When KT0.10 (which occurs when the
dosage interval - is made equal to, or less




Since, under such conditions, c-Kr _ 1K7, and
i_c-Kr The result shown in eq. (16) is
the same as obtained by substituting from
eq. (7) into eq. (9).
Another advantage of defining drug ac-
cumulation in terms of average amounts rather
than concentrations at a given time is that the
average amount of drug in the body at the
steady state is independent of the rate of ab-
sorption (providing the rate is not too slow
to reduce drug bioavailability), whereas the
maximum and minimum drug concentrations
at steady state are both functions of the rate
of absorption.
Summary
Pharmacokinetic analysis indicates that
patients with severely impaired renal
function should receive the same loading
dose of digoxin as patients with normal
renal function. The calculated loading
dose for both types of patients, however,
is appreciably lower than the usually
reeoniniended loading doses in the litera-
ture. The analysis has indicated that the
patients with severely impaired renal func-
tion should be administered maintenance
doses of digoxin which are only about
one half those administered to patients
with normal renal function. Under these
conditions, both types of patients will have
equal average amounts of digoxin in the
body (and in compartment 2 of the two-
compartment open model) at the steady
state. To achieve equal average steady-
state plasma concentrations, the mainte-
nance dose of the patients with severely im-
paired renal function would have to be
one third of the maintenance dose admiii-
istered to patients with normal renal func-
tion; the loading dose would have to be
about five times the maintenance dose for
the severely impaired renal patients, and
about two and a half times the mainte-
nance dose for the patients with normal
renal function. Thus, using the plasma
concentration criterion, the loading dose
in patients with severely impaired renal
(16) function would be two thirds of the load-
ing for patients with normal renal func-
tion, since
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